(Q38089641)

English

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis

scientific article published on 13 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Zu-Yao Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Xin-Yin Wu

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Ya-Fang Huang

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Meng-Yang Di

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Da-Yong Zheng

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Jin-Zhang Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Hong Ding

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Chen Mao

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Jin-Ling Tang

9

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

0 references

publication date

13 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

133

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1914-1925

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

The price tag on progress--chemotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

The case of the misleading funnel plot

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

RAF/RAS oncogenes and mismatch-repair status

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28153

21 January 2018

Identifiers

10.1002/IJC.28153

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38089641&oldid=2141351101"